Xiangguo Qiu

Summary

Affiliation: Public Health Agency of Canada
Country: Canada

Publications

  1. ncbi Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS Negl Trop Dis 6:e1575. 2012
  2. ncbi Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    Clin Immunol 141:218-27. 2011
  3. ncbi Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS ONE 4:e5547. 2009
  4. ncbi Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies
    Xiangguo Qiu
    National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Transl Med 4:138ra81. 2012
  5. ncbi Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Transl Med 4:158ra146. 2012

Collaborators

Detail Information

Publications5

  1. ncbi Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS Negl Trop Dis 6:e1575. 2012
    ..These results indicate that MAbs particularly when used as an oligoclonal set are a potential therapeutic for post-exposure treatment of EBOV infection...
  2. ncbi Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    Clin Immunol 141:218-27. 2011
    ..All 8 MAb improved survival rates by 33%-100% against a high dose lethal challenge with mouse-adapted ZEBOV. This work has important implications for further development of vaccines and immunotherapies for ZEBOV infection...
  3. ncbi Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses
    Xiangguo Qiu
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    PLoS ONE 4:e5547. 2009
    ..Zaire ebolavirus (ZEBOV) produces a lethal viral hemorrhagic fever in humans and non-human primates...
  4. ncbi Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies
    Xiangguo Qiu
    National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Transl Med 4:138ra81. 2012
    ..These data highlight the important role of antibodies to control EBOV replication in vivo, and support the use of mAbs against a severe filovirus infection...
  5. ncbi Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates
    Gary Wong
    Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
    Sci Transl Med 4:158ra146. 2012
    ..These results highlight the relevance of total ZGP-specific IgG levels as a meaningful correlate of protection against ZEBOV exposure...